Screener
ClearPoint Neuro CLPT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | March 31, 2026 / (Unaudited) | December 31, 2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value; 90,000,000 shares authorized at March 31, 2026 and December 31, 2025; 29,986,639 and 29,368,760 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 300 | 294 |
| Additional paid-in capital | 239,468 | 238,995 |
| Shares to be issued | 5,535 | 5,641 |
| Accumulated deficit | (226,462) | (216,910) |
| Total stockholders’ equity | 18,841 | 28,020 |
| Total liabilities and stockholders’ equity | $93,416 | $97,747 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's total equity?
- ClearPoint Neuro (CLPT) reported total equity of $18.84M in Q1 2026.
- How has ClearPoint Neuro's total equity changed year-over-year?
- ClearPoint Neuro's total equity decreased by 5.7% year-over-year, from $19.99M to $18.84M.
- What is the long-term trend for ClearPoint Neuro's total equity?
- Over 5 years (2020 to 2025), ClearPoint Neuro's total equity has grown at a 63.8% compound annual growth rate (CAGR), from $2.38M to $28.02M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about ClearPoint Neuro's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude